Labcorp Holdings Inc. $LH Shares Bought by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Labcorp Holdings Inc. (NYSE:LH) by 59.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,209 shares of the medical research company’s stock after purchasing an additional 1,932 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Labcorp were worth $1,390,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in LH. Brighton Jones LLC purchased a new position in Labcorp in the 4th quarter worth $991,000. Integrated Wealth Concepts LLC grew its stake in Labcorp by 7.9% during the 1st quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company’s stock valued at $565,000 after purchasing an additional 177 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Labcorp by 52.2% in the first quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company’s stock valued at $82,353,000 after purchasing an additional 121,304 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in shares of Labcorp in the second quarter valued at about $5,873,000. Finally, First Trust Advisors LP raised its stake in shares of Labcorp by 83.2% in the second quarter. First Trust Advisors LP now owns 86,046 shares of the medical research company’s stock worth $22,588,000 after purchasing an additional 39,087 shares during the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Insider Transactions at Labcorp

In other news, EVP Bryan T. Vaughn sold 234 shares of Labcorp stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $66,968.46. Following the completion of the transaction, the executive vice president directly owned 6,746 shares of the company’s stock, valued at $1,930,637.74. The trade was a 3.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Adam H. Schechter sold 5,903 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the sale, the chief executive officer directly owned 107,234 shares in the company, valued at $27,291,053. This trade represents a 5.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,991 shares of company stock valued at $1,796,696 in the last 90 days. 0.84% of the stock is currently owned by company insiders.

Labcorp Stock Performance

NYSE LH opened at $309.47 on Friday. The firm has a market capitalization of $25.38 billion, a P/E ratio of 25.60, a PEG ratio of 2.05 and a beta of 0.89. The stock has a 50-day simple moving average of $274.71 and a two-hundred day simple moving average of $271.01. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.54 and a current ratio of 1.80. Labcorp Holdings Inc. has a fifty-two week low of $244.52 and a fifty-two week high of $316.11.

Labcorp (NYSE:LH) last issued its earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. The firm had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.35 earnings per share. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, equities analysts forecast that Labcorp Holdings Inc. will post 18.31 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, August 28th. Labcorp’s dividend payout ratio is currently 23.82%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on LH. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Labcorp in a report on Wednesday, April 8th. Morgan Stanley raised their price target on shares of Labcorp from $308.00 to $338.00 and gave the stock an “overweight” rating in a research report on Friday. Weiss Ratings upgraded shares of Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. Robert W. Baird set a $352.00 price objective on shares of Labcorp in a report on Friday. Finally, Truist Financial increased their price objective on shares of Labcorp from $320.00 to $350.00 and gave the stock a “buy” rating in a research note on Friday. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $323.27.

Labcorp News Roundup

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp exceeded expectations in the second quarter, reporting adjusted EPS of $4.99 versus the $4.78 analyst consensus and revenue of $3.73 billion versus estimates of $3.71 billion. Revenue increased 5.8% year over year, supported by steady diagnostic-testing demand and growth in drug-development services. Reuters article
• Positive Sentiment: The company raised its 2026 adjusted EPS guidance to $18.10-$18.55, above the roughly $17.99-$18.00 consensus, while forecasting revenue of approximately $14.71 billion-$14.83 billion. Diagnostics Laboratories revenue rose 5.5%, and Biopharma Laboratory Services revenue increased 6.5%. Labcorp second-quarter results
• Positive Sentiment: Labcorp expanded its share-repurchase authorization by $1 billion, repurchased $353.8 million of stock during the quarter and paid $58.7 million in dividends. Truist Financial also raised its price target from $320 to $350 and assigned a “buy” rating, implying further upside from recent levels. Benzinga reference
• Neutral Sentiment: Management highlighted continued investment in oncology, consumer health and technology initiatives. The earnings call transcripts provide additional detail on demand trends, margins and the updated outlook. Labcorp Q2 earnings call transcript
• Negative Sentiment: Despite the earnings and revenue beats, LH shares fell in premarket trading and remain lower in active trading. The reaction indicates that investors may have viewed the results and raised outlook as insufficient relative to elevated expectations and the stock’s recent rally toward its 52-week high. Zacks market reaction
• Negative Sentiment: Recent insider-trading data shows company insiders made multiple sales and no purchases over the past six months, a potential sentiment headwind, although the transactions do not necessarily reflect management’s outlook. Quiver Quantitative report

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.